Navigation Links
Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
Date:9/8/2010

BALTIMORE, Sept. 8 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.  

B-Raf, a protein kinase, is a key part of a signaling pathway in the cell that leads to cell proliferation.  A mutation in B-Raf is implicated in a wide-range of cancers, including melanoma, colorectal and ovarian cancer.

Under the terms of the agreement, Champions will use its Biomerk Tumorgraft™ to test the effectiveness of CEP-32496 in various cancer indications.  "We are delighted to add Cephalon to Champions' client list.  The preclinical use of our highly-predictive Biomerk Tumorgraft™ platform will enable a greater understanding of the clinical potential of CEP-32496," said Elizabeth Bruckheimer, Ph.D., Vice President of Scientific Operations, Champions Biotechnology, Inc.  

Bruce Ruggeri, PhD, Senior Director, Oncology Research Drug Discovery at Cephalon stated, "We are excited to work with Champions.  These results may be critical in appropriately designing clinical trials to further support the development of this compound."

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts͐
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
10. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
11. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- The Physician-Patient Alliance for Health & Safety ... "Surviving Your Hospital Stay: Physician-Patient Alliance for Health ... A sentence was omitted from the release. ... is a member of the National Coalition to Promote ... the National Coalition to Promote Continuous Monitoring of Patients ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... 1 The Center for,Translational Molecular Medicine (CTMM) ... and development of new techniques for,the diagnosis and ... nine,projects will receive research funding amounting to a ... a broad spectrum of small and,medium-sized enterprises, major ...
... warmer,the American Heartworm Society (AHS) wants every pet owner ... risk it carries for pets., Although the risk ... mosquito population increases, the AHS recommends year-round,prevention for both ... pet owners will have their pets protected when they ...
Cached Medicine Technology:Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease 2Mosquito Season Approaching: American Heartworm Society Reminds Pet Owners of Risk 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held ... have to. , Instead of risking containment — or even destruction — of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital Tampa ... that was developed for targeted delivery of fluids to selected sites in the ... Florida Hospital Tampa with the device that provides direct, local delivery of chemotherapy ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... for years about the health risks of using the Chicago ... Chicago study, canoeing, kayaking, rowing, boating and fishing on the ... performing these same activities on other local waters -- a ... for swimmers at Lake Michigan beaches. The study is ...
... is providing a new route to get to and remove ... natural hole behind the molars, above the jawbone and beneath ... surgery, published in the October the Laryngoscope , the ... faster recovery and fewer complications than traditional approaches. And, because ...
... Oct. 25 (HealthDay News) -- ,Marijuana causes disruptions in ... people with schizophrenia, according to a new study. ... neurons in the brains of rats given a drug ... of marijuana. The effects of the drug on ...
... A new potential leukemia therapy targets only cancer cells, ... treatments affect cancer cells and healthy cells, causing significant ... and depression. This research is being presented at ... Meeting and Exposition in Washington, D.C., Oct. 23 ...
... TUESDAY, Oct. 25 (HealthDay News) -- Scientists have identified mutations ... have a potentially fatal blood clot after undergoing heart stent ... the drug Plavix (clopidogrel), a widely used blood thinner, and ... Oct. 26 issue of the Journal of the American ...
... Sox and Yankee fans alike sitting inches away from the television, ... away It might have been that very moment in 2003 when ... it might have been that very moment in 2004, when Boston,s Pokey ... devastation of 2003 began to fade from the memories of so many ...
Cached Medicine News:Health News:Boaters' risk of illness on Chicago River similar to other waterways 2Health News:Boaters' risk of illness on Chicago River similar to other waterways 3Health News:New 'scarless' surgery takes out tumors through natural skull opening 2Health News:Genes Could Highlight Plavix Users at Clot Risk After Stent 2Health News:A World Series to remember? 2
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Foreign body spud angled, lightly rounded tip....
... Manufactured from premium high ... high oxygen permeability. Standard ... Recommended for the following ... and abrasions. bullous keratopathy, ...
Guthrie fixation hook, sharp double prongs....
Medicine Products: